@article{6f69a93918e8408598254b91a901d47f,
title = "Impact of viral upper respiratory tract infection on the concentration of nasopharyngeal pneumococcal carriage among Kenyan children",
abstract = "Viral upper respiratory tract infection (URTI) predisposes to bacterial pneumonia possibly by facilitating growth of bacteria such as Streptococcus pneumoniae colonising the nasopharynx. We investigated whether viral URTI is temporally associated with an increase in nasopharyngeal pneumococcal concentration. Episodes of symptomatic RSV or rhinovirus URTI among children <5 years were identified from a longitudinal household study in rural Kenya. lytA and alu PCR were performed on nasopharyngeal samples collected twice-weekly, to measure the pneumococcal concentration adjusted for the concentration of human DNA present. Pneumococcal concentration increased with a fold-change of 3.80 (95%CI 1.95–7.40), with acquisition of RSV or rhinovirus, during 51 URTI episodes among 42 children. In repeated swabs from the baseline period, in the two weeks before URTI developed, within-episode variation was broad; within +/−112-fold range of the geometric mean. We observed only a small increase in nasopharyngeal pneumococcal concentration during RSV or rhinovirus URTI, relative to natural variation. Other factors, such as host response to viral infection, may be more important than nasopharyngeal pneumococcal concentration in determining risk of invasive disease.",
author = "Morpeth, {Susan C.} and Patrick Munywoki and Hammitt, {Laura L.} and Anne Bett and Christian Bottomley and Onyango, {Clayton O.} and Murdoch, {David R.} and Nokes, {D. James} and Scott, {J. Anthony G.}",
note = "Funding Information: We are grateful to the field, laboratory and data management teams for the household transmission parent study, and to the study participants. Thanks also go to John Ojal for statistical advice. This article is published with the permission of the director of the Kenya Medical Research Institute. This work was supported by the Wellcome Trust of Great Britain. SCM and LLH were supported by the Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) through a grant from Gavi, The Vaccine Alliance; JAGS [098532] and DJN [090853] were supported by research fellowships from The Wellcome Trust. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Funding Information: Competing Interests: LLH has received research funding from GlaxoSmithKline Biologicals, Pfizer Inc. and Merck. All other authors report no competing interests. Publisher Copyright: {\textcopyright} 2018, The Author(s).",
year = "2018",
month = dec,
day = "1",
doi = "10.1038/s41598-018-29119-w",
language = "English (US)",
volume = "8",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Research",
number = "1",
}